Diabetic retinopathy is an ocular microangiopathy.
Diabetic retinopathy is one of the main causes of acquiredblindness in the industrialized countries. Approximately 90% of all diabetic patients have retinopathy after twenty years.
Diabetes mel-litus can lead to changes in almost every ocular tissue. These include symp-toms of keratoconjunctivitis sicca, xanthelasma, mycotic orbital infections, transitory refractory changes, cataract, glaucoma, neuropathy of the optic nerve, oculomotor palsy. However, 90% of all visual impairments in diabetic patients are caused by diabetic retinopathy. The most common international nomenclature used to describe the various changes in diabetic retinopathy
(Table 12.1) is based on the classification of the Diabetic Retinopathy Study. A distinction is made between nonproliferative stages (1. mild, 2. moderate, 3. severe; Fig. 12.14) and proliferative stages (1. non-high-risk 2. high-risk; Fig. 12.15â€“12.17).
Diabetic retinopathy remains asymptomatic for a long time. Onlyin the late stages with macular involvement or vitreous hemorrhage will the patient notice visual impairment or suddenly go blind.
Diabetic retinopathy and its various stages (seeTable 12.1) are diagnosed by stereoscopic examination of the fundus with the pupil dilated. Ophthalmoscopy and evaluation of stereoscopic fundus photographs represent the gold standard. Fluorescein angiography is used to determine if laser treatment is indicated. The presence of rubeosis iridis is confirmed or excluded in slit-lamp examination with a mobile pupil, i.e., without the use of a mydriatic, and by gonioscopy of the angle of the anterior chamber.
A differential diagnosis must exclude other vascularretinal diseases, primarily hypertonic changes of the fundus (this is done by excluding the underlying disorder).
Clinically significant macular edema, i.e., macular edema thatthreatens vision, is managed with focal laser treatment at the posterior pole. Proliferative diabetic retinopathy is treated with scatter photocoagulation performed in three to five sessions.
Failure to perform regular ophthalmologic screening examina-tions in patients with diabetes mellitus is a negligent omission that exposes patients to the risk of blindness. Therefore, all type II diabetics should undergo ophthalmologic examination upon diagnosis of the disorder, and type I diabetics should undergo ophthalmologic examination within five years of the diagnosis. Thereafter, diabetic patients should undergo ophthal-mologic examination once a year, or more often if diabetic retinopathy is present. Pregnant patients should be examined once every trimester.
Optimum control of blood glucose can pre-vent or delay retinopathy. However, diabetic retinopathy can occur despite optimum therapy. Rubeosis iridis (neovascularization in the iris) in prolifera-tive diabetic retinopathy is tantamount to loss of the eye as rubeosis iridis is a relentless and irreversible process.
The risk of blindness due to diabetic retinopathy can be reduced by optimum control of blood glucose, regular ophthalmologic examina-tion, and timely therapy, but it cannot be completely eliminated.